Clik here to view.
GSK Signs $120M Deal to Market DMab Overseas
Image via Wikipedia In an effort to boost its sales force without hiring more sales reps, Amgen announced on Tuesday that it has signed a deal with GlaxoSmithKline to co-market its osteoporosis...
View ArticleClik here to view.
Saving Haiti: One Donation at a Time (UPDATED 1/21)
Image by American Red Cross via Flickr It’s been less than three days since new broke of a massive earthquake in Haiti that all but leveled the struggling country. With thousands dead, a devastated...
View ArticleProlia: Runner Up in Pharm Exec Brand of the Year
This month, Pharm Exec magazine presents its Brand of the Year. Here, Brittany Agro profiles one of the runners-up, Amgen’s osteoporosis treatment, Prolia. A joint meeting of the European Calcified...
View ArticleBiomedical Innovation in Trouble
The time and cost of developing new drugs are rising, venture capitalists make no return on investments in biopharma R&D, and other countries are boosting support in this area while U.S. policy...
View ArticleBattle Escalates over 340B Drug Pricing Program
What was once an obscure federal policy for providing low-cost drugs to safety-net hospitals has grown into a program that requires extensive discounting to one-third of the nation’s hospitals and...
View ArticleClik here to view.
Forbes Health Summit: Industry Leaders Ponder the New World of...
In health care, it is the lowly consumer who is now calling the shots, driving product and process innovation in areas ranging from electronic medical records [EMR] to retail health clinics. This was...
View ArticleAbbVie, Amgen, and Roche Most Exposed to Biosimilar Competition
While biosimilar products have been launched in Asia and Europe, they are at least three years away in the US, according to a new report on the global biosimilar drugs market. The Moody’s Investors...
View ArticleNew "Blockbusters" Will Triple Acute Coronary Syndrome Market
The launch of several drugs with “extraordinary blockbuster potential” will more than triple the acute coronary syndrome (ACS) treatment market, from $12.3 billion in 2013 to $43.4 billion by 2023,...
View ArticleAmgen and Sandoz in Legal Battle Over Biosimilar Application
By Randi Hernandez In a landmark lawsuit over the first biosimilar application, Amgen is suing Sandoz for unlawfully refusing to follow the patent resolution protocol laid out by the rules of the...
View Article
